Dr. Shilpa Gupta is a genitourinary oncologist at the Cleveland Clinic, Cleveland, OH, USA.
She has expertise and interest in novel targeted therapy and immunotherapy trials across genitourinary cancers. She has led several early and late-phase clinical trials including investigator-initiated trials with novel combinations in bladder cancer and testicular cancer, for example, neoadjuvant use of nivolumab and platinum doublet in muscle-invasive bladder cancer, enzalutamide and platinum-doublet in metastatic androgen receptor-positive bladder cancer, brentuximab and bevacizumab in CD30+ germ cell tumors.
Disclosures
- Consulting: Merck, BMS, Seattle Genetics, Astrazeneca, Pfizer